key: cord-0712151-94x0bf18
authors: Hadi, Yousaf B.; Naqvi, Syeda Fatima; Kupec, Justin T.
title: Risk of COVID-19 in Patients Taking Proton Pump Inhibitors
date: 2020-10-01
journal: Am J Gastroenterol
DOI: 10.14309/ajg.0000000000000949
sha: 7f03f87e8d730e768ad7bb32f9a61ac3a1c88e45
doc_id: 712151
cord_uid: 94x0bf18

nan

We recently read with great interest the important and timely study by Almario et al. (1) regarding increased risk of patients taking proton pump inhibitors (PPIs) testing positive for COVID-19. The authors concluded that an independent relationship exists between PPI use and a positive COVID-19 test. If the results are valid, these findings have major implications for the gastroenterological community. At our institution, we have already received phone calls from patients regarding their PPI use and its impact on their risk for COVID-19.

We believe, however, that the study has a major limitation that remains unaddressed even after revisions. The authors mention in the methods section that they collected information from participants on whether they received testing for the virus (not all participants were tested for COVID-19). The number of participants tested for COVID-19 is not provided in the study, either in the whole cohort or in the individual groups. We believe that this omission limits the conclusions of the study, and this information is vital for drawing valid conclusions.

The number of people who received testing in the 2 cohorts needs to be provided and compared to prevent any bias resulting from a disproportionate number of people in the PPI cohort having been tested for COVID-19. In fact, the most important determinant in getting a positive COVID-19 test is getting tested for COVID-19 itself! If people in the non-PPI user group received fewer tests, it could result in fewer positive tests as well. This is especially important because it has been shown that many patients with COVID-19 remain asymptomatic (2) , and thus, disproportionate testing in groups is a major concern.

Patients taking "stronger" medications, who are more "initiated" into the healthcare system, could be more likely to get tested and hence could report more positives. Comparing, or at least mentioning, the proportion of participants in both groups who were tested is thus essential in our opinion. The inclusion of other comorbid conditions in the regression does not eliminate such bias.

A subgroup analysis of only the people who were tested for the virus should also eliminate such bias and can be performed with the data available with the researchers. Otherwise, the regression model should include history of being tested as a covariate. If the authors provide the number of patients who received testing in the 2 groups, this would reduce the limitedness of the conclusions.

A secondary observation is that many people are prescribed PPIs for nonheartburn/ gastrointestinal-related symptoms. These people include those at high risk of bleeding, among others. This cohort remains uncaptured by the study because the survey was asked to be filled by people who were reported gastrointestinal symptoms only. Perhaps, further studies should include patients taking PPIs (for any indication) who are tested for COVID-19 and compare such a group with patients tested for COVID-19 who are not taking PPIs to eliminate these concerns. Financial support: None to report. Potential competing interests: None to report.

Increased risk of COVID-19 among users of proton pump inhibitors

COVID-19: Four fifths of cases are asymptomatic, China figures indicate